Current anti-IL-17A therapies (secukinumab and ixekizumab) are associated with unwanted off-target immunogenic effects, lymphocytosis and thrombocytopenia.34 As such, numerous clinical trials are currently investigating new biologic therapies targeting IL-17 biology/function to improve clinical outcomes in patients with IMIDs.35 Here, we evaluated in vivo the neutralising potential of Ab-IPL-IL-17 on IL-17A, IL-17F and IL-17A/F heterodimer production. This evidence concerns the gene IL17A and Thrombocytopenia.